Clinical trial
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
NCT00117598 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00117598 |
|---|---|
| Title | Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) |
| Official title | An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL) |
| Acronym | OPTIMAL |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Temsirolimus (CCI-779), Investigator's choice |
| Enrollment | 169 |
| Start date | May 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Jan 1, 2011 |
| First posted | Jul 7, 2005 |
| Last update posted | Mar 30, 2015 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, France, Germany, Italy, Netherlands and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: